Superluminal Medicines
Superluminal Medicines is a Boston biotech. Its Hyperloop platform combines AI/ML, protein dynamics, structural biology and agentic cryo-EM to design small molecules against GPCRs. Its lead program is a biased MC4R agonist for rare genetic and hypothalamic obesity, and the company expects to start Phase 1 by the end of 2026. It earns revenue from partnerships and develops its own pipeline. It signed an Eli Lilly collaboration in 2025 and closed a $60M Series B led by BVF Partners in September 2026, after a $33M seed in 2023 and a $120M Series A in 2024.
Funding
Every round, secondary, debt facility or acquisition involving Superluminal Medicines that AI Lounge tracks, newest first. Latest: Series B on Sep 3, 2026.
Timeline · 2
In the news
Members see every AI company on AI Lounge with revenue, funding, valuation and investors, searchable and sortable, free.
Create my free account →Log in